Retinal degeneration in a rodent model of Smith-Lemli-Opitz syndrome: electrophysiologic, biochemical, and morphologic features.
OBJECTIVE
To assess the electrophysiologic, histologic, and biochemical features of an animal model of Smith-Lemli-Opitz syndrome (SLOS).


METHODS
Sprague-Dawley rats were treated with AY9944, a selective inhibitor of 3beta-hydroxysterol-Delta(7)-reductase (the affected enzyme in SLOS). Dark- and light-adapted electroretinograms were obtained from treated and control animals. From each animal, 1 retina was analyzed by microscopy, and the contralateral retina plus serum samples were analyzed for sterol composition. The main outcome measures were rod and cone electroretinographic amplitudes and implicit times, outer nuclear layer (ONL) thickness, rod outer segment length, pyknotic ONL nucleus counts, and the 7-dehydrocholesterol/cholesterol mole ratio in the retina and serum.


RESULTS
By 10 weeks' postnatal age, rod and cone electroretinographic wave amplitudes in AY9944-treated animals were significantly reduced and implicit times were significantly increased relative to controls. Maximal rod photoresponse and gain values were reduced approximately 2-fold in treated animals relative to controls. The ONL thickness and average rod outer segment length were reduced by approximately 18% and 33%, respectively, and ONL pyknotic nucleus counts were approximately 4.5-fold greater in treated animals relative to controls. The retinal pigment epithelium of treated animals contained massive amounts of membranous/lipid inclusions not routinely observed in controls. The 7-dehydrocholesterol/cholesterol mole ratios in treated retinas and serum samples were approximately 5:1 and 9:1, respectively, whereas the ratios in control tissues were essentially zero.


CONCLUSIONS
This rodent model exhibits the key biochemical hallmarks associated with SLOS and displays electrophysiologic deficits comparable to or greater than those observed in the human disease. Clinical Relevance These results predict retinal degeneration in patients with SLOS, particularly those with the more severe (type II) form of the disease, and may be more broadly relevant to other inborn errors of cholesterol biosynthesis. This animal model may also be of use in evaluating therapeutic treatments for SLOS and in understanding the slow phototransduction kinetics observed in patients with SLOS.
Fliesler
Steven J
SJ
Department of Ophthalmology, Saint Louis University School of Medicine, MO 63104-1540, USA. fliesler@slu.edu
Peachey
Neal S
NS
Richards
Michael J
MJ
Nagel
Barbara A
BA
Vaughan
Dana K
DK
D000818:Animals; D000924:Anticholesteremic Agents / Q000633:toxicity; D002784:Cholesterol / Q000097:blood; D003623:Dark Adaptation; D003684:Dehydrocholesterols / Q000097:blood; D004195:Disease Models, Animal; D004594:Electrophysiology; D004596:Electroretinography; D005260:Female; D010857:Pigment Epithelium of Eye; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D012160:Retina / Q000378:metabolism / Q000503:physiopathology* / Q000648:ultrastructure; D012162:Retinal Degeneration / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*; D019082:Smith-Lemli-Opitz Syndrome / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*; D001371:trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride / Q000633:toxicity
D000924:Anticholesteremic Agents; D003684:Dehydrocholesterols; D001371:trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride; D002784:Cholesterol; C016705:7-dehydrocholesterol